Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 25 |
| Active Pipeline (Recruiting Now) | 16 (10) |
| Completed vs Stopped Early | 3 / 6 (24.0%) |
| Median Closed Actual Enrollment | 43 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Kantonsspital St. Gallen | Sankt Gallen | 16 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06401980 | Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase II | RECRUITING |
| NCT07020065 | Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metast | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Swiss Cancer Institute Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.